Sumanirol je razvijen za lečenjeParkinsonove bolesti isindroma nemirnih nogu. Mada on nije odobren za kliničku upotrebu,[4][5] on je korisno oruđe za bazna istraživanja neurobioloških mehanizama koji su bazirani na modu dejstva dopaminskog D2 receptora (vs. D1, D3, D4, i D5 receptora).[3]
^Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy.Romero, Arthur G.; Darlington, William H.; McMillan, Moses W. (1997). „Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy”.Journal of Organic Chemistry.62 (19): 6582—6587.doi:10.1021/jo970526a..
^Barone P, Lamb J, Ellis A, Clarke Z (2007). „Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease”.Movement Disorders : Official Journal of the Movement Disorder Society.22 (4): 483—9.PMID17115380.doi:10.1002/mds.21191.
^Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (2007). „Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study”.Sleep Medicine.8 (2): 119—27.PMID17239657.doi:10.1016/j.sleep.2006.05.018.
Y
.PMID 20346635.doi:10.1016/j.euroneuro.2010.02.011. 
